Breaking News Instant updates and real-time market news.

CRON

Cronos Group

$20.60

1.15 (5.91%)

, CVSI

CV Sciences

$0.00

(0.00%)

12:56
03/25/19
03/25
12:56
03/25/19
12:56

NJ Senate calls off marijuana vote without needed support, NJ.com reports

New Jersey state Senate President Stephen Sweeney said in a statement provided to NJ Advance Media that "While we are all disappointed that we did not secure enough votes to ensure legislative approval of the adult use cannabis bill today, we made substantial progress on a plan that would make significant changes in social policy," according to NJ.com's Brent Johnson. It is expected that New Jersey lawmakers will schedule another vote on marijuana legalization this year, but it's unclear when, the report noted. Publicly traded companies in the space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Tilray (TLRY). Reference Link

CRON

Cronos Group

$20.60

1.15 (5.91%)

CVSI

CV Sciences

$0.00

(0.00%)

IGC

India Globalization Capital

$2.13

-0.1 (-4.48%)

ACB

Aurora Cannabis

$9.28

0.3 (3.34%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

MLCPF

Changed to MEDIF

$0.00

(0.00%)

CANN

General Cannabis

$0.00

(0.00%)

APHA

Aphria

$9.58

0.04 (0.42%)

CGC

Canopy Growth

$44.06

-0.34 (-0.77%)

TLRY

Tilray

$67.70

0.32 (0.47%)

  • 26

    Mar

CRON Cronos Group
$20.60

1.15 (5.91%)

03/14/19
COWN
03/14/19
NO CHANGE
COWN
Narrow U.S. cannabis bills have better prospects than broad ones, says Cowen
Cowen analyst Jaret Seiberg said it is hard for him to see a scenario in the 116th Congress in which Senate Majority Leader Mitch McConnell holds a vote on legislation to fully legalize cannabis, as too many senators see no political upside for McConnell to schedule such a vote. Given this view, Seiberg believes that prospects are better for narrower bills that could get attached to spending packages and other measures than for broader bills that would legalize recreational use. Of the narrower bills introduced in the U.S. so far, Seiberg believes the SAFE Act on cannabis banking has the best shot before the 2020 election. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Tilray (TLRY).
03/11/19
03/11/19
DOWNGRADE

Underperform
Cronos Group downgraded to Underperform, valuation 'elevated,' says BMO Capital
As previously reported, BMO Capital downgraded Cronos Group to Underperform from Market Perform. Analyst Tamy Chen believes Cronos' production ramp is behind other licensed producers and views valuation as "elevated."
03/05/19
COWN
03/05/19
INITIATION
COWN
Market Perform
Cronos Group initiated with a Market Perform at Cowen
Cowen analyst Vivien Azer started Cronos Group (CRON) with a Market Perform rating and C$29 price target. The analyst likes the company's story as an asset-light, global low-cost producer with operational support and invested capital from Altria Group (MO). However, Azer says the stock's current valuation prevents her from taking a more constructive position at this time.
03/11/19
BMOC
03/11/19
DOWNGRADE
BMOC
Underperform
Cronos Group downgraded to Underperform from Market Perform at BMO Capital
CVSI CV Sciences
$0.00

(0.00%)

02/14/19
COWN
02/14/19
NO CHANGE
COWN
SAFE Act should pass House, Senate path less clear, says Cowen
After the House Financial Services financial institutions subcommittee held a hearing on legislation that would permit banks to provide service to cannabis companies that are in compliance with state law, Cowen analyst Jaret Seiberg said he believes the hearing went well enough for the SAFE Act to pass the committee and the full House later this year. However, the path forward in the Senate is "less clear," said Seiberg. The analyst, whose base call remains that the House passes the SAFE Act and other cannabis laws and that the Senate then pushes through a package before the end of the 116th Congress, expects "positive news by the end of 2020 for cannabis companies," he tells investors. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Tilray (TLRY).
01/24/19
NORL
01/24/19
INITIATION
Target $8
NORL
Outperform
CV Sciences initiated with an Outperform on growing CBD demand at Northland
Northland analyst Mike Grondahl initiated CV Sciences with an an Outperform and $8 price target saying recent passage of the 2018 Farm Bill will drive a wave of CBD demand.
11/07/18
ADAM
11/07/18
NO CHANGE
ADAM
Midterms broadly positive for U.S. cannabis industry, says Canaccord
Canaccord analyst Bobby Burleson says that as expected, yesterday's midterms delivered several wins for the U.S. cannabis industry, including the passage of three state ballot measures on legalization, key gubernatorial victories by pro-cannabis candidates, and the retaking of the House by Democrats. The analyst views these results as broadly positive for the U.S. cannabis industry. Publicly traded companies in the space include Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC) and Tilray (TLRY).
IGC India Globalization Capital
$2.13

-0.1 (-4.48%)

10/17/18
MSCO
10/17/18
NO CHANGE
MSCO
Morgan Stanley says pot legalization could pose risk to Canadian auto insurers
Morgan Stanley analyst Kai Pan noted that academic studies do not agree on the potential impact on car accidents from legalized recreational use of marijuana, but he still believes Canada's legalization could pose a risk to Canadian auto insurers. IFC, the largest auto insurer in Canada, is not immune to this challenge but given its long-term outperformance versus peers and strong claims management, Pan thinks the company should be better positioned in addressing this challenge, he tells investors. Publicly traded companies in the cannabis space include Aurora Cannabis (ACBFF), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC) and Tilray (TLRY).
ACB Aurora Cannabis
$9.28

0.3 (3.34%)

03/13/19
MITR
03/13/19
UPGRADE
MITR
Buy
Aurora Cannabis upgraded to Buy from Hold at GMP Securities
03/13/19
MITR
03/13/19
UPGRADE
Target $15
MITR
Buy
Aurora Cannabis upgraded to Buy from Hold at GMP Securities
GMP Securities analyst Martin Landry upgraded Aurora Cannabis to Buy from Hold and raised his price target to $15 from $9.50. In a research note to investors, Landry says new high profile strategic advisor Nelson Peltz could be "instrumental" in facilitating partnership talks with large consumer packaged goods companies. Additionally, the analyst says its fully-licensed Bradford and Aurora Sky facilities should alleviate inventory concerns.
03/13/19
03/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Carnival (CCL) upgraded to Buy from Neutral at Goldman Sachs analyst Stephen Grambling citing the company accelerating its net unit growth from 2.5% in the last 3 years to 5% over the next 3 years and also believes that concerns about net yields in Europe are overblown. 2. Sanderson Farms (SAFM) upgraded to Neutral from Underweight at JPMorgan with analyst Ken Goldman saying he now views the stock's upside/downside risk as balanced. 3. Axis Capital (AXS) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying Axis is positioned for strong underwriting improvement. 4. Broadridge (BR) upgraded to Outperform from Market Perform at Raymond James with analyst Patrick O'Shaughnessy saying he believes Broadridge's current valuation offers investors an attractive entry point into a differentiated, high barrier to entry business. 5. Aurora Cannabis (ACB) upgraded to Buy from Hold at GMP Securities with analyst Martin Landry saying new high profile strategic advisor Nelson Peltz could be "instrumental" in facilitating partnership talks with large consumer packaged goods companies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CNTTF CannTrust Holdings
$0.00

(0.00%)

02/25/19
JEFF
02/25/19
INITIATION
JEFF
Buy
CannTrust Holdings initiated with a Buy at Jefferies
Jefferies analyst Owen Bennett initiated coverage of nine cannabis stocks, stating that his base-case "conservative" assumption is that the cannabis industry can grow in size to over $50B by 2029 from $17B in 2019. He started CannTrust Holdings with a Buy rating and C$15 price target, citing his view that it has "one of the strongest medical businesses in Canada" and "has slipped under the radar," maybe due to its non-U.S. listing.
02/25/19
02/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Antares Pharma (ATRS) initiated with an Outperform at Cowen. 2. New Fortress Energy (NFE) initiated with a Buy at Citi and Stifel, an Overweight at Morgan Stanley, an Equal Weight at Barclays and an Oupterform at JMP Securities and Evercore ISI. 3. Aurora Cannabis (ACB), CannTrust Holdings (CNTTF), Flowr (FLWPF), Organigram (OGRMF) and The Green Organic Dutchman (TGODF) initiated with a Buy at Jefferies, Canopy Growth (CGC) and Emerald Health Therapeutics (EMHTF) initiated with a Hold, Cronos Group (CRON) and HEXO (HEXO) initiated with an Underperform. 4. Pulse Biosciences (PLSE) initiated with a Buy at H.C. Wainwright. 5. Beacon Roofing (BECN) initiated with a Neutral at Buckingham, while the firm initiated BMC Stock Holdings (BMCH) and TopBuild (BLD) with a Buy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MLCPF Changed to MEDIF
$0.00

(0.00%)

CANN General Cannabis
$0.00

(0.00%)

APHA Aphria
$9.58

0.04 (0.42%)

02/21/19
02/21/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. At Home Group (HOME) initiated with a Hold at Loop Capital. 2. Harmonic (HLIT) initiated with a Buy at Stifel. 3. Atkore (ATKR) initiated with a Neutral at Credit Suisse. 4. BioTime (BTX) and Verrica Pharmaceuticals (VRCA) were initiated with a Buy at H.C. Wainwright. 5. Aphria (APHA), KushCo Holdings (KSHB), and HEXO Corp (HEXO) were initiated with a Buy at Seaport Global, while Canopy Growth (CGC), Aurora Cannabis (ACB), and Tilray (TLRY) were initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/21/19
GHSC
02/21/19
INITIATION
Target $18
GHSC
Buy
Aphria initiated with a Buy at Seaport Global
Seaport Global analyst Brett Hundley initiated Aphria with a Buy rating and $18 price target, citing its positioning as a low-cost Canadian licensed producer and its move to establish broad-based international relationships.
CGC Canopy Growth
$44.06

-0.34 (-0.77%)

03/08/19
JEFF
03/08/19
INITIATION
Target $61
JEFF
Underperform
Tilray falls after Jefferies starts with Underperform rating, $61 target
Shares of Tilray (TLRY) are moving lower after Jefferies analyst Owen Bennett initiated coverage of the shares with an Underperform rating and $61 price target. Underperform is Jefferies' equivalent of a sell rating. Shares of Tilray are down 4%, or $2.97, to $66.75 in premarket trading. Bennett's 10-year discounted cash flow-driven valuation suggests the stock is "too expensive for its outlook." As a company wanting to be a global leader, the names that Tilray needs to be compared to are Canopy Growth (CGC) and Aurora Cannabis (ACB), Bennett tells investors in a research note. However, Tilray's Canada medical share is not in the top four and recent consumer feedback is "not inspiring," adds the analyst. Further, he believes the company's approach to recreational "does not appear as well thought through" and that its "optionality" in the U.S. is "less impressive." As such, Bennett struggles to justify Tilray's current valuation.
03/05/19
COWN
03/05/19
INITIATION
COWN
Outperform
Cowen starts Aurora at Outperform, replaces Canopy as top pick
Cowen analyst Vivien Azer initiated coverage of Aurora Cannabis (ACB) with an Outperform rating and C$14 price target. Aurora is "uniquely positioned" to drive leadership in both market share and profitability with the Canadian adult use market in the "early innings," Azer tells investors in a research note. Her analysis pegs Aurora's market share at an "impressive" 20% to date and shows the company has the number two position by in-stock SKU. Azer designated Aurora Cannabis as her Top Pick in cannabis, replacing Canopy Growth (CGC). Given that Canopy currently trades at 18 times estimated fiscal 2030 revenue estimates, Aurora's trading multiple "is defensible," says the analyst.
03/05/19
JEFF
03/05/19
NO CHANGE
JEFF
Hedge funds building short thesis on Canopy Growth, says Jefferies
In a research note summarizing early feedback from investors on his cannabis initiations last week, Jefferies analyst Owen Bennett says hedge funds appear to be building a short thesis on Canopy Growth (CGC). The thesis focuses on harvesting concerns, which in Q2 came in at 15,217kg and then 7,556kg in Q3, Bennett tells investors in a research note. He points out that Canopy has attributed the reduction to rotation timing between harvests. The "short view is it could be due to crop failure due to scaling up too quickly," the analyst contends. With this in mind, he believes Canopy Growth's Q4 results will be very closely watched. Bennett has a Hold rating on Canopy Growth.
TLRY Tilray
$67.70

0.32 (0.47%)

03/19/19
PIPR
03/19/19
NO CHANGE
Target $90
PIPR
Overweight
Piper maintains Overweight rating, $90 target on Tilray after Q4 results
After Tilray reported a Q4 EBITDA loss of ($17.8M), Piper Jaffray analyst Michael Lavery says he does not expect positive earnings in near-term, as the company will remain in investment mode to drive growth. The Canadian market may become profitable as it ramps up, contends the analyst, but he does not expect positive total company EBITDA over the next five-to-seven quarters. However, Lavery expects strong industry growth long-term, and believes Tilray is well positioned to be one of several likely winners. He maintains an Overweight rating on the shares with a $90 price target.
03/08/19
03/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tilray (TLRY) initiated with an Underperform at Jefferies. 2. BB&T (BBT) initiated with a Buy at Odeon Capital. 3. Syros Pharmaceuticals (SYRS) initiated with an Outperform at JMP Securities. 4. W&T Offshore (WTI) initiated with a Buy at Stifel. 5. Ichor Holdings (ICHR) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

AUPH

Aurinia Pharmaceuticals

$15.76

0.31 (2.01%)

21:03
12/09/19
12/09
21:03
12/09/19
21:03
Syndicate
Aurinia Pharmaceuticals 11.1M share Secondary priced at $15.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

GDI

Gardner Denver

$33.90

-0.19 (-0.56%)

20:08
12/09/19
12/09
20:08
12/09/19
20:08
Downgrade
Gardner Denver rating change  »

Gardner Denver downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDI

Gardner Denver

$33.90

-0.19 (-0.56%)

19:56
12/09/19
12/09
19:56
12/09/19
19:56
Downgrade
Gardner Denver rating change  »

Gardner Denver downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTCWY

Deutsche Wohnen

$0.00

(0.00%)

19:50
12/09/19
12/09
19:50
12/09/19
19:50
Downgrade
Deutsche Wohnen rating change  »

Deutsche Wohnen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEGXF

Segro

$0.00

(0.00%)

19:49
12/09/19
12/09
19:49
12/09/19
19:49
Downgrade
Segro rating change  »

Segro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BORR

Borr Drilling

$6.60

0.46 (7.49%)

19:30
12/09/19
12/09
19:30
12/09/19
19:30
Initiation
Borr Drilling initiated at Goldman Sachs »

Borr Drilling initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSG

Inseego

$6.89

-0.05 (-0.72%)

19:26
12/09/19
12/09
19:26
12/09/19
19:26
Syndicate
Breaking Syndicate news story on Inseego »

Inseego files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSV

Forty Seven

$30.44

16.04 (111.39%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
Forty Seven to hold an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

ARQL

ArQule

$19.71

10.035 (103.77%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
ArQule »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

XNCR

Xencor

$41.41

0.39 (0.95%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
Xencor to host analyst & investor meeting »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

ABR

Arbor Realty

$14.78

(0.00%)

19:20
12/09/19
12/09
19:20
12/09/19
19:20
Syndicate
Arbor Realty 6.5M share Spot Secondary priced at $14.14 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

STRM

Streamline Health

$1.25

-0.04 (-3.10%)

18:59
12/09/19
12/09
18:59
12/09/19
18:59
Hot Stocks
Streamline Health delaying Q3 results to resolve amortization charge »

Streamline Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLOK

NortonLifeLock

$25.43

-0.02 (-0.08%)

, INTC

Intel

$56.52

-0.28 (-0.49%)

18:55
12/09/19
12/09
18:55
12/09/19
18:55
Periodicals
McAfee weighs combination with NortonLifeLock, WSJ reports »

NortonLifeLock (NLOK) has…

NLOK

NortonLifeLock

$25.43

-0.02 (-0.08%)

INTC

Intel

$56.52

-0.28 (-0.49%)

AVGO

Broadcom

$314.49

-1.68 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 19

    Dec

  • 23

    Jan

TGTX

TG Therapeutics

$9.28

2.17 (30.52%)

18:55
12/09/19
12/09
18:55
12/09/19
18:55
Conference/Events
TG Therapeutics to host investor & analyst meeting »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

NTNX

Nutanix

$33.87

-0.725 (-2.10%)

18:41
12/09/19
12/09
18:41
12/09/19
18:41
Hot Stocks
Nutanix CEO: We are transitioning to a subscription-based model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

  • 16

    Dec

SFIX

Stitch Fix

$25.17

1.04 (4.31%)

, MDB

MongoDB

$131.03

-0.19 (-0.14%)

18:33
12/09/19
12/09
18:33
12/09/19
18:33
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Stitch…

SFIX

Stitch Fix

$25.17

1.04 (4.31%)

MDB

MongoDB

$131.03

-0.19 (-0.14%)

PHR

Phreesia

$29.01

-0.09 (-0.31%)

CDMO

Avid Bioservices

$5.85

0.05 (0.86%)

MTN

Vail Resorts

$231.30

-1.43 (-0.61%)

TOL

Toll Brothers

$41.40

0.515 (1.26%)

EQ

Equillium

$4.00

-0.03 (-0.74%)

SUPN

Supernus

$22.69

-0.145 (-0.63%)

A

Agilent

$81.68

-0.545 (-0.66%)

HEPA

Hepion Pharmaceuticals

$5.61

0.4 (7.68%)

ROAD

Construction Partners

$20.56

0.66 (3.32%)

CASY

Casey's General Stores

$175.33

-0.47 (-0.27%)

CHWY

Chewy

$24.17

-0.76 (-3.05%)

LVGO

Livongo Health

$27.40

-0.6 (-2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 12

    Dec

  • 18

    Dec

  • 19

    Dec

BLUE

Bluebird Bio

$76.72

-2.79 (-3.51%)

, BMY

Bristol-Myers

$61.32

1.38 (2.30%)

18:24
12/09/19
12/09
18:24
12/09/19
18:24
Hot Stocks
Bluebird Bio, Bristol-Myers present update on Phase 1 study of bb21217 »

Bluebird bio (BLUE) and…

BLUE

Bluebird Bio

$76.72

-2.79 (-3.51%)

BMY

Bristol-Myers

$61.32

1.38 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

BA

Boeing

$351.25

-2.74 (-0.77%)

18:22
12/09/19
12/09
18:22
12/09/19
18:22
Periodicals
Former Boeing employee Pierson to testify at U.S. House hearing, Reuters says »

An ex-Boeing employee who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

OXY

Occidental Petroleum

$37.34

-0.07 (-0.19%)

18:21
12/09/19
12/09
18:21
12/09/19
18:21
Hot Stocks
Occidental Petroleum director buys 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

OXY

Occidental Petroleum

$37.34

-0.07 (-0.19%)

18:14
12/09/19
12/09
18:14
12/09/19
18:14
Hot Stocks
Occidental Petroleum director buys 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

EDIT

Editas Medicine

$30.34

-0.6 (-1.94%)

18:02
12/09/19
12/09
18:02
12/09/19
18:02
Hot Stocks
Editas Medicine announces in vivo proof-of-concept data for EDIT-301 »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSB

Mesabi Trust

$23.93

0.71 (3.06%)

, CLF

Cleveland-Cliffs

$8.52

0.38 (4.67%)

17:56
12/09/19
12/09
17:56
12/09/19
17:56
Hot Stocks
Mesabi Trust initiates arbitration against Northshore Mining, Cleveland-Cliffs »

The Trustees of Mesabi…

MSB

Mesabi Trust

$23.93

0.71 (3.06%)

CLF

Cleveland-Cliffs

$8.52

0.38 (4.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFBC

First Financial Bancorp

$24.67

0.12 (0.49%)

17:51
12/09/19
12/09
17:51
12/09/19
17:51
Hot Stocks
First Financial Bancorp chairman Davis sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRE

Green Plains

$14.26

-0.49 (-3.32%)

17:47
12/09/19
12/09
17:47
12/09/19
17:47
Hot Stocks
Green Plains CEO Todd Becker sold over 607K in company shares »

Green Plains CEO Todd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$111.12

-2.02 (-1.79%)

17:43
12/09/19
12/09
17:43
12/09/19
17:43
Hot Stocks
Medtronic director buys 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.